A randomized clinical trial comparing metabolic parameters after 48 weeks of standard‐ and low‐dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV‐infected South African patients

No abstract is available for this paper.

• Publication year

  2014

• Venue

  HIV Medicine

• Publication date

  2014-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/hiv.12074PMID 23980620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cited by this paper
• The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV‐infected patients: a randomized trial

  2013cited by this paper
• Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

  2013cited by this paper
• Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2013cited by this paper
• Approaches to tenofovir and abacavir drug shortages in South Africa: A guide for clinicians

  2012cited by this paper
• Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.

  2011cited by this paper
• A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects

  2011cited by this paper
• The Pathophysiology of HIV-/HAART-Related Metabolic Syndrome Leading to Cardiovascular Disorders: The Emerging Role of Adipokines

  2011cited by this paper
• Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.

  2010cited by this paper
• Factors associated with renal dysfunction within an urban HIV‐infected cohort in the era of highly active antiretroviral therapy

  2009cited by this paper
• Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction

  2009cited by this paper
• HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial

  2009cited by this paper
• Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage.

  2009cited by this paper
• Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.

  2008cited by this paper
• Cost and Cost-Effectiveness of Switching From Stavudine to Tenofovir in First-Line Antiretroviral Regimens in South Africa

  2008cited by this paper
• Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels: The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study

  2008cited by this paper
• Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients

  2008cited by this paper
• Metabolic Function and the Prevalence of Lipodystrophy in a Population of HIV-Infected African Subjects Receiving Highly Active Antiretroviral Therapy

  2007cited by this paper
• Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study

  2007cited by this paper
• Serum leptin concentrations and fat redistribution in HIV‐1‐infected children on highly active antiretroviral therapy

  2007cited by this paper
• Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

  2007cited by this paper
• Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.

  2007cited by this paper
• Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study

  2007cited by this paper
• The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients

  2006cited by this paper
• Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

  2006cited by this paper
• Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

  2005cited by this paper
• Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to Didanosine and Stavudine vs. Abacavir and Lamivudine

  2005cited by this paper
• C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study

  2004cited by this paper
• Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV‐infected patients

  2004cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Inflammatory markers and the risk of coronary heart disease in men and women.

  2004cited by this paper
• Combination antiretroviral therapy and the risk of myocardial infarction

  2003cited by this paper
• Combination antiretroviral therapy and the risk of myocardial infarction.

  2003cited by this paper
• Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

  2003cited by this paper
• Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

  2003cited by this paper
• Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Body Habitus Changes and Metabolic Alterations in Protease Inhibitor‐Naive HIV‐1‐Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors

  2002cited by this paper
• Adverse effects of antiretroviral therapy.

  2000cited by this paper
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

  1999cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Decline in deaths from AIDS due to new antiretrovirals.

  1997cited by this paper
• Plasma lipids in HIV‐infected patients: a prospective study in 95 patients

  1994cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Accentuated Risk of Tenofovir-Associated Nephrotoxicity and Hepatoxicity among HIV Patients in Nigeria: Empirical Evidence from a Cohort Study

  2019cites this paper
• Dyslipidemia among rural and urban HIV patients in south-east Malawi

  2018cites this paper
• Prevalence and risk factors of metabolic syndrome in HIV‐infected adults at three urban clinics in a post‐conflict setting, eastern Democratic Republic of the Congo

  2018cites this paper
• Alterations of Glucose Metabolism in HIV-Infected Patients

  2018cites this paper
• Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial

  2018cites this paper
• Complete Phase-Out Stavudine Based Regimens in the Treatment of HIV-Infection: is it True That Stavudine Hasn’t Any Benefit Today? A Review

  2017influential citation
• Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.

  2017cites this paper
• Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten

  2017cites this paper
• Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?

  2017cites this paper
• Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?

  2017cites this paper
• Cardio-metabolic effects of anti-retroviral treatment in the Cape Winelands region of South Africa

  2016cites this paper
• Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients

  2016cites this paper
• Clinical and Immunological Effects of a Reduced Daily Dose of Stavudine among Antiretroviral Naïve HIV-infected Individuals in Dar es Salaam, Tanzania: A Randomized, Controlled Study

  2015cites this paper
• A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings

  2015cites this paper
• Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis

  2015cites this paper
• Insulin Resistance Change and Antiretroviral Therapy Exposure in HIV-Infected and Uninfected Rwandan Women: A Longitudinal Analysis

  2015cites this paper
• Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.

  2014cites this paper
• Update on metabolic issues in HIV patients.

  2014cites this paper
• The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review

  2008cites this paper